Back to all papers

Global practice patterns of MR-linac use in head and neck radiotherapy: a survey by the international MR-Linac consortium.

November 5, 2026pubmed logopapers

Authors

Belliveau C,Hansen CR,Terhaard C,de Ridder M,Bahig H,Renz P,Palafox GAC,Mansha MA,Xing D,Senanayake T,Zukauskaite R,Lonkvist CK,Filion E,Boeke S,Thorwarth D,di Monale MB,Wong K,Castelli J,Fuller CD,Moreno A,Ng SP

Affiliations (18)

  • Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada.
  • Department of Oncology, Odense University Hospital, Odense, Denmark.
  • Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Radiation Oncology Department, UMC, Utrecht, the Netherlands.
  • Allegheny Health Network, USA.
  • Hospital Almater, Mexico.
  • Dow University of Health Sciences, Karachi, Pakistan.
  • Townsville University Hospital, Australia.
  • St George's Cancer Care Centre, New Zealand.
  • Herlev and Gentofte Hospital, Denmark.
  • University Hospital Tübingen, Germany.
  • Section for Biomedical Physics, Department of Radiation Oncology, Eberhard Karls University Tübingen, Tübingen, Germany.
  • ASST Spedali Civili and Università di Brescia, Italy.
  • Royal Marsden Hospital, UK.
  • Centre Eugene Marquis, France.
  • Department of Radiation Oncology, Division of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Radiation Oncology, Austin Health, Melbourne, Australia.

Abstract

Head-and-neck (HN) cancers remain prevalent, and most patients require radiotherapy as part of their treatment. Anatomical changes during treatment can alter dose distribution, potentially impacting both tumor control and toxicity. Magnetic resonance-guided linear accelerators (MR-Linacs) enable adaptive radiotherapy by integrating high-resolution soft-tissue imaging with on-table plan adaptation. However, global practice patterns, expert priorities, and barriers to implementation of this emerging technology remain incompletely characterized. We therefore conducted a survey to evaluate perceived benefits and barriers to MR-guided radiotherapy in head-and-neck cancers. A cross-sectional survey was distributed to experts within the Head and Neck MR-Linac Consortium, assessing five domains: current clinical use, treatment delivery approaches, automation, re-irradiation practices, and clinical trial priorities. Thirty-six experts from four continents responded (67%, <i>n</i> = 24/36 from academic centers). Although 86% (<i>n</i> = 31/36) reported access to MR-Linac technology, only 28% (<i>n</i> = 10/36) treated HN patients, with a median of 2.5 patients treated per respondent (IQR 1-20). Adaptive strategies varied, including adapt-to-position (40%, <i>n</i> = 4/10), online adapt-to-shape (40%, <i>n</i> = 4/10), and offline adapt-to-shape (20%, <i>n</i> = 2/10). Reported barriers included prolonged treatment times, limited staffing resources, and suboptimal plan quality. Key priorities for improvement included volumetric modulated arc therapy (VMAT) implementation, faster dose delivery, AI-assisted auto-contouring, and standardized quality assurance workflows. Functional imaging, particularly diffusion-weighted imaging, and dose accumulation reporting were also highly valued. For future clinical trials, early identification of responders was considered essential, weekly adapt-to-shape workflows were deemed feasible, and stereotactic body radiotherapy (SBRT) was preferred for re-irradiation. Cost-effectiveness analyses were consistently highlighted as important. This international survey of MR-Linac practice in head-and-neck cancer demonstrates substantial interest in the technology but limited clinical uptake, largely due to workflow inefficiencies and heterogeneous adaptive strategies. Advances in treatment delivery efficiency, AI-driven automation, standardized quality assurance, and dose accumulation methodologies will be essential to support broader clinical integration and to guide future trial design<b>.</b>

Topics

Journal Article

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAISlice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.